The Role of Checkpoint Inhibition in Non-Small Cell Lung Cancer.

Conclusion: Treatment of NSCLC is constantly changing, and new immune checkpoint inhibitors have shown promising results. Clinical trials are examining their use in the adjuvant setting and in combination with other therapies, and these combination therapies have the potential to show even greater benefits and broader applications than the individual drugs themselves. PMID: 29230122 [PubMed]
Source: Ochsner Journal - Category: General Medicine Tags: Ochsner J Source Type: research